Stock GEN GENOMED SPÓLKA AKCYJNA
Add to a list
To use this feature you must be a member
Log inSign up

Financials Genomed Spólka Akcyjna

Equities

GEN

PLGNOMD00024

Biotechnology & Medical Research

End-of-day quote Warsaw S.E.
Other stock markets
 18:00:00 2024-06-24 EDT 		5-day change 1st Jan Change
28 PLN -.--% Intraday chart for Genomed Spólka Akcyjna -.--% -6.04%
05-13 Genomed Spólka Akcyjna Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
02-14 Genomed Spólka Akcyjna Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 CI

Valuation

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Capitalization 1 33.56 36.2 43.6 45.19 44.92 39.37
Enterprise Value (EV) 1 30.05 33.35 39.98 40.33 41.43 34.11
P/E ratio 22.7 x 36.1 x 106 x 36.5 x 133 x 42.5 x
Yield 3.94% - - - - -
Capitalization / Revenue 1.81 x 1.84 x 2.32 x 2.27 x 2.2 x 1.75 x
EV / Revenue 1.62 x 1.7 x 2.13 x 2.03 x 2.03 x 1.52 x
EV / EBITDA 11.1 x 17.3 x 34.2 x 19.2 x 38.7 x 18.4 x
EV / FCF 134 x -319 x 53.7 x 34.1 x -66 x 21.7 x
FCF Yield 0.75% -0.31% 1.86% 2.94% -1.52% 4.6%
Price to Book 4.45 x 5.02 x 5.77 x 5.14 x 4.92 x 3.91 x
Nbr of stocks (in thousands) 1,321 1,321 1,321 1,321 1,321 1,321
Reference price 2 25.40 27.40 33.00 34.20 34.00 29.80
Announcement Date 19-05-24 20-05-27 21-05-25 22-05-23 23-05-23 24-05-24
1PLN in Million2PLN
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net sales 1 18.59 19.67 18.75 19.89 20.46 22.48
EBITDA 1 2.711 1.927 1.167 2.097 1.072 1.852
EBIT 1 1.817 1.075 0.4677 1.338 0.3565 1.244
Operating Margin 9.77% 5.47% 2.49% 6.72% 1.74% 5.53%
Earnings before Tax (EBT) 1 1.818 1.083 0.4088 1.333 0.3689 1.052
Net income 1 1.479 1.002 0.4123 1.238 0.338 0.9262
Net margin 7.96% 5.09% 2.2% 6.22% 1.65% 4.12%
EPS 2 1.120 0.7582 0.3120 0.9370 0.2558 0.7010
Free Cash Flow 1 0.2248 -0.1046 0.7438 1.184 -0.6281 1.571
FCF margin 1.21% -0.53% 3.97% 5.95% -3.07% 6.99%
FCF Conversion (EBITDA) 8.29% - 63.71% 56.46% - 84.8%
FCF Conversion (Net income) 15.2% - 180.41% 95.64% - 169.56%
Dividend per Share 2 1.000 - - - - -
Announcement Date 19-05-24 20-05-27 21-05-25 22-05-23 23-05-23 24-05-24
1PLN in Million2PLN
Estimates

Balance Sheet Analysis

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net Debt 1 - - - - - -
Net Cash position 1 3.51 2.85 3.63 4.86 3.49 5.26
Leverage (Debt/EBITDA) - - - - - -
Free Cash Flow 1 0.22 -0.1 0.74 1.18 -0.63 1.57
ROE (net income / shareholders' equity) 21.8% 13.6% 5.58% 15.1% 3.77% 9.65%
ROA (Net income/ Total Assets) 12.7% 7.36% 3.08% 8.22% 2.15% 6.91%
Assets 1 11.64 13.61 13.38 15.06 15.7 13.4
Book Value Per Share 2 5.700 5.460 5.720 6.660 6.910 7.610
Cash Flow per Share 2 2.660 2.160 3.350 3.680 2.640 3.980
Capex 1 1.42 0.79 1.01 0.52 0.25 0.2
Capex / Sales 7.65% 4.04% 5.36% 2.59% 1.2% 0.91%
Announcement Date 19-05-24 20-05-27 21-05-25 22-05-23 23-05-23 24-05-24
1PLN in Million2PLN
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
GENOMED SPÓLKA AKCYJNA Stock Genomed Spólka Akcyjna
-6.04% 9.2M
MODERNA, INC. Stock Moderna, Inc.
+22.96% 45.51B
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
-7.83% 38.52B
LONZA GROUP AG Stock Lonza Group AG
+38.34% 38.13B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
+27.06% 30.74B
CELLTRION, INC. Stock Celltrion, Inc.
-13.50% 26.03B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+12.34% 25.92B
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+44.24% 14.13B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+35.77% 12.73B
BIO-TECHNE CORPORATION Stock Bio-Techne Corporation
-6.22% 11.29B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. GEN Stock
  4. Financials Genomed Spólka Akcyjna